Gary R. Lichtenstein, MD
Professor of Medicine at the Hospital of the University of Pennsylvania
Director, IBD Program, Hospital of the University of Pennsylvania
Department: Medicine
Contact information
3400 Civic Center Boulevard
753 Perelman Center for Advanced Medicine
South Pavilion
Philadelphia, PA 19104
753 Perelman Center for Advanced Medicine
South Pavilion
Philadelphia, PA 19104
Office: 215-349-8222
Fax: 215-349-5915
Fax: 215-349-5915
Publications
Education:
BA (Chemistry)
University of Pennsylvania, 1980.
MD
Mount Sinai School of Medicine, 1984.
Permanent linkBA (Chemistry)
University of Pennsylvania, 1980.
MD
Mount Sinai School of Medicine, 1984.
Description of Research Expertise
My research focuses on inflammatory bowel disease specifically Crohn's disease and Ulcerative Colitis. My particular focuses include1.) medical therapy of inflammatory bowel disease,
2.) safety of current medical therapy for IBD, and
3.) natural history of disease
Description of Clinical Expertise
Inflammatory Bowel DiseaseCrohn's Disease
Ulcerative Colitis
Selected Publications
L. Peyrin-Biroulet, A. Dignass, W.J. Sandborn, K.G. Huang,M. Germinaro, R. Wilson,H. Zhang, B. Chen, M. Chen, T. Hisamatsu, B.G. Feagan, J. Panés, G.R. Lichtenstein. : The Effect of Guselkumab Induction Therapy on Inflammatory Biomarkers In Patients With Moderately To Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Results Through Week 12. United European Gastroenterology Journal 2022; 10 (Supplement 8); October 2022 10(8), October 2022.Lichtenstein GR: Spotlight on COVID-19. Gastroenterol Hepatol (N Y). July 2022.
Lichtenstein GR: Managing Patients With Helicobacter pylori Infection. Gastroenterol Hepatol (N Y). 18(6), June 2022.
Klapproth J and Lichtenstein Gary R.: Fistulizing Crohn’s Disease. In Pediatric Inflammatory Bowel Disease, 4th Edition. Eds. Mamula P, Markowitz JE, Baldassano R. Springer Publishers Springer (eds.). June 2022.
Bhavana Bhagya Rao, Abhik Bhattacharya, Lichtenstein Gary R. : New Non-anti-TNF- alpha Biologic Therapies for the Treatment of Inflammatory Bowel Disease. In Pediatric Inflammatory Bowel Disease, 4th Edition. Eds. Mamula P, Markowitz JE, Baldassano R. June 2022.
Lichtenstein GR.: Inflammatory Bowel Disease in Cecil’s Textbook of Medicine. Edited by Lee Goldman and Andrew I. Schafer. Elsevier Publisher. Philadelphia, PA. 25th Edition. 2022. Chapter June 2022.
Lichtenstein GR : Treatment for Patients With Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y) 18(5): 231, May 2022.
Millie D. Long, Raymond K. Cross, Gary R. Lichtenstein, Jonathan Calkwood, Ashwini Pai Marc Pondel, Harris Ahmad, Lorna Charles, Ayanbola Elegbe, AnnKatrin Petersen, James K. Sheffield, Adil Javed, Jason K. Hou, Miguel D. Regueiro, Douglas C. Wolf, Alessandro Armuzzi: LONG-TERM CARDIAC SAFETY OF OZANIMOD IN PHASE 3 CLINICAL PROGRAM OF ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS. Gastroenterology 2022; 162; 7 (Supplement S5-S6). Abstract 15. 162(7): S5-S6, May 2022.
David T. Rubin, Stephan R. Vavricka, Alessandro Armuzzi, Marla C. Dubinsky Ala I. Sharara, Irene Modesto, Fellmann Marc, Liguori Giusseppina, Lawendy Nervin, Cadatla Mary Jane, Lichtenstein, Gary R. : EFFICACY AND SAFETY OF TOFACITINIB IN ULCERATIVE COLITIS PATIENTS WITH EXTRAINTESTINAL MANIFESTATIONS IN OCTAVE OPEN. Gastroenterology 2022; 162; 7 (Supplement S-979). Abstract Tu 1480 162(7), May 2022.
Jessica R. Allegretti, David T. Rubin, Brian Bressler, Kuan-Hsiang G. Huang, Nicole Shipitofsky, Matthew Germinaro, Hongyang Zhang, Jewel Johanns, Brian G. Feagan, William J. Sandborn, Bruce E. Sands, Tadakazu Hisamatsu, Gary R. Lichtenstein, Julian Panes, Axel Dignass: THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 2B QUASAR STUDY RESULTS THROUGH WEEK 12. Gastroenterology 2022; 162; 7 (Supplement S-963-964). Abstract Tu 1446 162(7), May 2022.